Digging deeper into ESMO this week

As the dust begins to settle on another eventful ESMO congress we will continue to bring you analysis of the meeting's key data readouts over the coming days.

Be part of the conversation

On Wednesday, you can join FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and me to discuss our five biggest takeaways from ESMO 2021 – register for free here.

One of the topics up for debate is the impressive data presented for AstraZeneca and Daiichi Sankyo's Enhertu in HER2-positive breast cancer and what impact these results could have on the broader field of antibody-drug conjugates (ADCs) - already a hotbed of investment, compelling science and notable R&D momentum.

At ESMO, AstraZeneca also provided a tantalising glimpse at potential combination agents that could unlock greater efficacy for immunotherapies, thanks to encouraging data from the Phase II COAST study in Stage III non-small-cell lung cancer (NSCLC).

Physician intelligence

To provide further insight on how new results presented at ESMO could change treatment practice in breast cancer, we are also fielding a number of snap-polls to US and European based oncologists this week…

…gauging reaction not only to new data for Enhertu, but updated results for Merck & Co.'s Keytruda in metastatic triple-negative breast cancer and Novartis' Kisqali in HR+/HER2-negative patients.

If you want us to let you know when results from these polls will be available click on the links above.

We will also be speaking to key opinion leaders in the fields of lung cancer, colorectal cancer and gastric cancer to ascertain how new data presented at ESMO could change potentially treatment practice.

Thanks for reading

Simon King – Executive Editor

To read more ViewPoints articles, click here.